Jürgen Fortin is the founder and CEO of CNSystems. He is also a university lecturer and responsible for the company’s intellectual property being the author of 80 patents and several publications on current and future noninvasive technologies.
Please log into your account to view faculty contact details.
CEO CNSystems, Austria
Syncope is a heterogeneous syndrome with complex underlying mechanisms. The spectrum of patients presenting with syncope is broad, which requires appropriate, often individualized diagnosis paths. “Patients presenting with syncope, a sudden transient loss of consciousness, require appropriate, often individualized diagnosis and treatment.” 1 Syncope is a heterogeneou
READ MORE
Long COVID patients suffer from autonomic dysfunction with persistent long-term symptoms. CNSystems’ non-invasive technology significantly contributes to a well-founded cardiovascular diagnosis of COVID-19 survivors and enables a quick check of treatment efficacy. Key Points Many patients who survive acute COVID-19 infection suffer from ongoing symptoms including breathlessness, palpitatio
READ MORE
Initial Orthostatic Hypotension (OH) is described as a rapid and transient drop in blood pressure associated with the increased risk of falls, fractures and syncope, especially in the ageing population (Tran et al. 2021). As prevalence is high, the problem is evident, but due to limited access to reliable continuous diagnostic methods, the detection of OH is restricted. Experts demand continuous...
READ MORE
P atients and their families often fear surgical interventions due to possible complications during the procedure and falsely assume to have survived the most dangerous part when reaching post-anesthetic care units. 1 However, postoperative hypotension more often occurs in the wards, causing myocardial infarction and death, 3,4 as it largely remains undetected. 5 47% of po
READ MORE
The rapid global distribution of the Coronavirus and the fear of collapsing healthcare systems have forced hospitals to concentrate on the treatment of COVID-19 patients and allocate their resources accordingly. As a consequence up to 80% of the elective cardiovascular (CV) interventions have been indefinitely postponed.1 This measure resulted in a number of alarming developments. One was that the...
READ MORE
The rapid global distribution of COVID-19 is challenging healthcare systems worldwide. In many countries hospitals and ICU departments are overloaded or fear a potential collapse - the optimal allocation of healthcare resources is required. Healthcare professionals are forced to treat severely ill patients with limited access to ventilation equipment, qualified intensive care personnel or protective...
READ MORE
Heart Failure (HF) is a major and public health problem as it affects at least 26 million people worldwide and will dramatically increase with an ageing population. Currently 5.7 million people suffer from HF in the US with an expected 46% increase in prevalence by 2030.[1] This is an alarming number especially when accounting for increasing health care cost. In the US around $31 billion, (10%...
READ MORE
How can we get the most common, costly, and modifiable cardiovascular risk factor under control? Cardiovascular disease (CVD) is the number one cause of death with an upward trend beyond 30% and a tripling in costs between 2010 and 2030, placing a significant economic burden on public healthcare services. 1,2,3 The most common risk factor for developing CVD is hypertension 1 affec
READ MORE
Aspects & challenges - Approaches & tools Head-up-tilt testing (HUTT) and autonomic function testing are essential diagnostic procedures in syncope assessment. With the advent of unique innovative methods to noninvasively monitor beat-to-beat blood pressure, cardiac output, total peripheral resistance as well as autonomic regulation, highly efficient tools to assess cardiovascular and autonom
READ MORE
